Partnership is first investment under Merck Serono Ventures’ €10 million Israel Bioincubator Program.
The corporate venture arm of Germany’s Merck Serono SA is collaborating with Compugen Ltd. to establish a new company, Neviah Genomics Ltd., which will discover, develop and market novel biomarkers for drug toxicity.
Announced June 25, the Neviah collaboration is the first investment under Merck Serono Ventures’ Israel Bioincubator program, established by Merck...
Linerixibat, GSK's treatment for cholestatic pruritus in patients with primary biliary cholangitis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.
Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.
